Compile Data Set for Download or QSAR
Report error Found 27 Enz. Inhib. hit(s) with all data for entry = 6626
TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142039BDBM142039(US8927577, 35 | US8927577, 118 | US8927577, 20)
Affinity DataKi:  14nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142041BDBM142041(US8927577, 22)
Affinity DataKi:  25nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142039BDBM142039(US8927577, 35 | US8927577, 118 | US8927577, 20)
Affinity DataKi:  39nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142042BDBM142042(US8927577, 23)
Affinity DataKi:  50nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142038BDBM142038(US8927577, 117 | US8927577, 32 | US8927577, 19)
Affinity DataKi:  53nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142038BDBM142038(US8927577, 117 | US8927577, 32 | US8927577, 19)
Affinity DataKi:  74nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142030BDBM142030(US8927577, 31 | US8927577, 30 | US8927577, 11)
Affinity DataKi:  76nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142035BDBM142035(US8927577, 16)
Affinity DataKi:  91nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142030BDBM142030(US8927577, 31 | US8927577, 30 | US8927577, 11)
Affinity DataKi:  101nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142037BDBM142037(US8927577, 18)
Affinity DataKi:  109nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142040BDBM142040(US8927577, 21)
Affinity DataKi:  133nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142046BDBM142046(US8927577, 27)
Affinity DataKi:  160nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142020BDBM142020(US8927577, 1)
Affinity DataKi:  173nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142029BDBM142029(US8927577, 10)
Affinity DataKi:  198nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142032BDBM142032(US8927577, 13)
Affinity DataKi:  199nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142022BDBM142022(US8927577, 3)
Affinity DataKi:  240nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142031BDBM142031(US8927577, 12)
Affinity DataKi:  242nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142021BDBM142021(US8927577, 2)
Affinity DataKi:  280nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142036BDBM142036(US8927577, 17)
Affinity DataKi:  360nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142024BDBM142024(US8927577, 5)
Affinity DataKi:  452nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142034BDBM142034(US8927577, 15)
Affinity DataKi:  479nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142028BDBM142028(US8927577, 9)
Affinity DataKi:  531nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142048BDBM142048(US8927577, 29)
Affinity DataKi:  930nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142027BDBM142027(US8927577, 8)
Affinity DataKi:  979nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142030BDBM142030(US8927577, 31 | US8927577, 30 | US8927577, 11)
Affinity DataKi:  1.24E+3nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142025BDBM142025(US8927577, 6)
Affinity DataKi:  1.86E+3nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 142023BDBM142023(US8927577, 4)
Affinity DataKi:  7.36E+3nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2015
Entry Details
US Patent